InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,251.60
(
-0.04%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
84.90
(
-0.12%
)
Bitcoin
63,910.26
(
-1.40%
)
Post# of 252279
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119885
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: AlpineBV_Miller post# 76292

Monday, 04/20/2009 8:30:41 PM

Monday, April 20, 2009 8:30:41 PM

Post# of 252279

DNDN: I should note that label extensions are not necessary to get Provenge to blockbuster status in North America, IMO of course.

There may be a significant number of men who will want to use Provenge in early-stage disease even if they have to pay out of pocket to get it. For this reason, DNDN would probably be wise not to overplay their hand and set too high a price.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up